Medifolin

Calcium folinate, the active ingredient in Medifolin, is a folate analog presented as an oral formulation for oral use. It is employed to rescue normal cells from antifolate toxicity, to supplement folate in deficiency states, and as an adjunct in certain chemotherapy protocols.

GNH USA supplies Medifolin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Medifolin (calcium folinate) is used in clinical settings that involve folate metabolism or antifolate therapy. - High‑dose methotrexate rescue: restores folate pools and reduces methotrexate‑related toxicity. - Combination chemotherapy adjunct: enhances efficacy of regimens that include antifolate agents. - Folate deficiency treatment: provides a bioavailable source of reduced folate for patients with inadequate dietary intake or malabsorption.

Adverse reactions may occur with calcium folinate therapy and are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Vomiting: occasional episodes, usually self‑limited. - Diarrhea: transient loose stools. - Elevated liver enzymes: mild, reversible increase. - Skin rash: mild erythematous eruption.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Bone marrow suppression: pancytopenia or severe neutropenia. - Hepatic failure: marked elevation of transaminases or jaundice. - Renal toxicity: acute kidney injury in susceptible individuals. - Severe cutaneous adverse reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing calcium folinate, clinicians should consider several safety measures. - Renal function: assess baseline creatinine and monitor during therapy. - Hepatic function: check liver enzymes before and during treatment. - Pregnancy: use only if clearly indicated, after risk‑benefit evaluation. - Concurrent antifolate therapy: avoid overlapping use that may blunt rescue effect. - Drug interactions: review all concomitant medications for potential folate pathway interference. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Calcium folinate may interact with other medicines; some combinations require avoidance, others close monitoring.

Major Interactions (Avoid): - Methotrexate: concurrent use can diminish rescue efficacy. - Trimethoprim: may increase folate antagonism and toxicity. - Pemetrexed: additive antifolate effect raises risk of severe toxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: may affect renal clearance of calcium folinate. - Penicillins: can interfere with folate metabolism pathways. - Phenytoin: may reduce folate levels, necessitating dose adjustment.